Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NFPET 89Zr-Bevacizumab PET/CT imaging in NF2 patients
2024-512860-75-00Phase 2Authorised
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab zirconium Zr-89 in neurofibromatosis type 2 (NF2) and acoustic neuroma, sponsored by Leiden University Medical Center. Primary endpoint: Correlation of pre-treatment 89Zr-bevacizumab PET/CT with hearing and radiographic response. Planned start Oct 2024; status: authorised.
02
Drugs
bevacizumab zirconium Zr-89
03
Conditions
neurofibromatosis type 2 (NF2)acoustic neuroma
Beyond the preview
Go deeper on 2024-512860-75-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512860-75-00.